Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia

International Journal of Cancer

Volumn 122, Issue 4, 2008, Pages 864-870

  Zhigang, Zhao ^a   Wenlu, Shen ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Chemoprevention; Flutamide; Prostate cancer (PCa); Prostate stem cell antigen (PSCA); Prostatic intraepithelial neoplasia (PIN)

Indexed keywords

ANDROGEN; FLUTAMIDE; MESSENGER RNA; PLACEBO; PROSTATE STEM CELL ANTIGEN; MEMBRANE PROTEIN; PSCA PROTEIN, HUMAN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOLLOW UP; GENE EXPRESSION; HUMAN; IN SITU HYBRIDIZATION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; STOMACH DISEASE; TREATMENT OUTCOME; GENETICS; METABOLISM; MIDDLE AGED; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; FLUTAMIDE; HUMANS; IN SITU HYBRIDIZATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 38349056454     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23150     Document Type: Article

References (38)

1. Szarka CE, Grana G, Engstrom PF. Chemoprevention of cancer. Curr Probl Cancer 1994;18:6-10.
2. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994;12:851-73.
3. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovitch L, Malone WA, Crowell JA, Sigman CC. Chemoprevention of prostate cancer: concepts and strategies. Eur Urol 1999;35:342-50.
4. Kim HL, Yang XJ. Prevalence of high-grade prostatic intraepithelial neoplasia and its relationship to serum prostate specific antigen. Im Braz J Urol 2002;28:413-17.
5. Colanzi P, Santinelli A, Mazzucchelli R, Pomante R, Montironi R. Prostatic intraepithelial neoplasia and prostate cancer: analytical evaluation. Adv Clin Path 1998;2:271-84.
6. Brawer MK, Bigler SA, Sohlberg OE, Nagle RB, Lange PH. Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology 1991;38:103-7.
7. Langer JE, Rovner ES, Coleman BG, Yin D, Arger PH, Malkowicz SB, Nisenbaum HL, Rowling SE, Tomaszewski JE, Wein AJ, Jacobs JE. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996;155:228-31.
8. Aboseif S, Shinohara K, Weidner N, Narayan P, Carroll PR. The significance of prostatic intraepithelial neoplasia. Br J Urol 1995;76:355-9.
9. Civantos EF, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM, Soloway MS. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 1995;75:1634-41.
10. Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994;44:91-5.
11. Wheeler TM. Influence of irradiation and androgen ablation on prostatic intraepithelial neoplasia. Eur Urol 1996;30:261-4.
12. Lieberman R. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology 2001;58 (Suppl 1):83-90.
13. Bostwick DG, Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 2001;58(2, Suppl 1):91-3.
14. Bostwick DG, Neumann R, Qian J, Cheng L. Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention. Eur Urol 1999;35:492-5.
15. Bostwick DG, Aquilina JW. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials. J Cell Biochem Suppl 1996;25:156-64.
16. Brogden RN, Clissold SP. Flutamide: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs 1989;38:185-203.
17. Labrie F. Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 1993;72:3816-27.
18. Luo S, Martel C, Chen C, Labrie C, Candas B, Singh SM, Labrie F. Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology 1997;50:913-9.
19. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, David E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95:1735-40.
20. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-96.
21. Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, Said J, Reiter RE. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001;61:4660-5.
22. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffee EM, Yeo CJ, Cameron JL, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001;61:4320-4.
23. Elsamman EM, Fukumori T, Tanimoto S, Nakanishi R, Takahashi M, Toida K, Kanayama HO. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int 2006;98:668-73.
24. Ross S, Spencer SD, Holcomb I, Tan C, Hongo JA, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-53.
25. Zhao ZG, Shen WL. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Jpn J Clin Oncol 2004;34:414-19.
26. Zhao ZG, Shen WL. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer. Prostate 2007;67:1143-51.
27. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986;17:64-71.
28. Epstein JI, Grignon DJ, Humphrey PA, McNeal JE, Sesterhenn IA, Troncoso P, Wheeler TM. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 1995;19:873-6.
29. Zhao ZG, Shen WL. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 2005;65:299-305.
30. Albert SR, Novotny PJ, Sloan JA, Danella J, Bostwick DG, Sebo TJ, Blute ML, Fitch TR, Levitt R, Lieberman R, Loprinzi CL. Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial. Am J Ther 2006;13:291-7.
31. Lefkowitz GK, Sidhu GS, Torre P, Lepor H, Taneja SS. Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urology 2001;58:999-1003.
32. Lefkowitz GK, Taneja SS, Brown J, Melamed J, Lepor H. Follow-up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002;168:1415-8.
33. Izawa JI, Lega I, Downey D, Chin JL, Luke PP. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer? BJU Int 2005;96:320-3.
34. Dubey P, Wu H, Reiter RE, Witte ON. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res 2001;61:3256-61.
35. Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000;27:95-103.
36. Watabe T, Lin M, Donjacour AA, Cunha GR, Witte ON, Reiter RE. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci USA 2002;99:401-6.
37. Bahrenberg G, Brauers A, Joost HG, Jakse G. PSCA expression is regulated by phorbol ester and cell adhesion in the bladder carcinoma cell line RT112. Cancer Lett 2001;168:37-43.
38. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 2002;16:2323-37.